Guillain-Barré syndrome (GBS) is an autoimmune polyneuropathy and a leading cause of nonpoliovirus-associated acute flaccid paralysis worldwide. In most cases, GBS follows an infectious event, most commonly Campylobacter jejuni, which induces antibodies against bacterial ganglioside-mimicking lipooligosaccharides. Those antibodies can cross-react with human neuronal gangliosides and drive neuropathy. Clinically, many patients recover as anti-ganglioside antibody titers decline and systemic immunostimulation resolves.
This study reports that roughly 10% of clinically confirmed GBS patients maintain high circulating anti-ganglioside antibody titers more than a decade after recovery. The presence of persistent autoantibodies did not correlate with ongoing neuropathic damage in the assays performed, indicating a dissociation between titer and pathogenicity in these recovered individuals.
To assess neurotoxic potential, the investigators used a human pluripotent stem cell-derived sensory neuron model combined with human complement. This in vitro system was used to compare the effects of paired sera from the same patients collected during acute disease and after clinical recovery.
When tested in this model, acute-phase sera from GBS patients produced neuropathic effects, whereas recovered-phase sera from the same individuals did not cause neuron degeneration under the same experimental conditions. These functional assays therefore demonstrated that persistent anti-ganglioside antibodies in some recovered patients lack effector functions required to damage neurons in this human-relevant model.
The study evaluated paired sera from individual patients to directly compare properties of antibodies present during acute neuropathy versus those remaining after recovery. Functional differences in the ability to cause neuronal injury were observed between acute and recovered sera despite comparable or high antigen-binding titers in a subset of recovered samples.
This paired approach allowed identification of qualitative changes in antibody features that accompanied loss of neurotoxicity, rather than simple quantitative declines in antibody concentration alone.
Analysis of paired acute and recovered sera revealed shifts in IgG subclass composition and in antibody glycoforms. These biochemical differences are consistent with altered Fc-mediated effector functions between the two time points. The source reports both subclass and glycosylation changes as distinguishing features of recovered-phase antibodies compared with their acute-phase counterparts.
Such modifications can modulate interactions with complement and Fc receptors, providing a mechanistic basis for diminished neurotoxic activity despite persistent antigen binding.
The investigators specifically characterized isolated anti-GM1 ganglioside antibodies and found anti-inflammatory modifications on these recovered-phase antibodies. These glycoform changes are reported in the source as contributing to the loss of pathogenic effector functions.
Because anti-GM1 antibodies are among those implicated in GBS pathogenesis, the observed modifications provide a plausible explanation for why some recovered patients continue to harbor measurable autoantibodies without clinical or modeled neuronal injury.
Taken together, the data support a model in which post-infectious immune maturation or selection favors non-pathogenic antibody variants in some patients. Recovered individuals may therefore retain antibodies that bind ganglioside antigens but have diminished ability to activate complement or Fc-dependent effector pathways that lead to neuron degeneration.
The authors propose that these retained, non-pathogenic antibodies might still confer protective activity against the original trigger organism, Campylobacter jejuni, while no longer mediating damage to host neurons. The source does not provide additional clinical outcome data, population characteristics beyond the reported prevalence of persistent titers, or longitudinal mechanistic details beyond the assays and molecular features described.
Competing interests and funding
The source discloses that one author has a founding interest in a cell therapeutics company. Funding from the United States Department of Defense and the National Institutes of Health is listed. No further competing interests or detailed protocol-specific information were reported in the source document.